CoChat

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality

Open access
Zhang, Wenfeng, Xia, Ding, Li, Zhangyun, Zhou, Tao, Chen, Tingting, Wu, Zhengping, Zhou, Weihua, Li, Zilun, Li, Longkun, Xu, Jie · 2019 · Cell Death & Disease

Abstract

Triple-negative breast cancer (TNBC), defined as a tumor subtype that lacks ER, PR, and HER2, shows a poor prognosis due to its aggressive tumor biology and limited treatment options. Deregulation of Aurora kinase A (Aur-A), a member of the mitotic serine/threonine Aurora kinase family, and overactivation of the mTOR pathway commonly occur in multiple cancer types. We previously found that Aur-A activated the mTOR pathway and inhibited autophagy activity in breast cancer cell models. Whether and how Aur-A regulates mTOR in TNBC are still unclear. Here, we found that Aur-A and p-mTOR are highly expressed and positively associated with each other in TNBC cells and tissues. Inhibition or knockdown of Aur-A decreased p-mTOR and suppressed cell proliferation and migration, whereas overexpression of Aur-A increased p-mTOR levels and promoted cell proliferation and migration, which was significantly abrogated by simultaneous silencing of mTOR. Intriguingly, overexpression of Aur-A enhanced the expression of p-mTOR and p-ERK1/2, and silencing or inhibition of ERK1/2 blocked Aur-A-induced p-mTOR. However, silencing or inhibition of mTOR failed to reverse Aur-A-induced ERK1/2, indicating that Aur-A/ERK1/2/mTOR forms an oncogenic cascade in TNBC. We finally found that double inhibition of Aur-A and mTOR showed significant synergistic effects in TNBC cell lines and a xenograft model, indicating that Aur-A and mTOR are potential therapeutic targets in the TNBC subtype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-019-1855-z

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Expression of Aur-A and mTOR in breast cancer cell lines and TNBC human tissues. a Basal levels of Aur-A, p-mTOR, mTOR, and other proteins in breast cancer cell lines. b Aur-A and p-mTOR expression in TNBC human tissues. TNBC tissue microarrays were stained with Aur-A and p-mTOR and then photographed (Scale bars, 100 μm). c Association analysis of Aur-A and p-mTOR in TNBC. Data were analyzed by using SPSS software (P < 0.001, Pearson’s test)
Fig. 1 Expression of Aur-A and mTOR in breast cancer cell lines and TNBC human tissues. a Basal levels of Aur-A, p-mTOR, mTOR, and other proteins in breast cancer cell lines. b Aur-A and p-mTOR expression in TNBC human tissues. TNBC tissue microarrays were stained with Aur-A and p-mTOR and then photographed (Scale bars, 100 μm). c Association analysis of Aur-A and p-mTOR in TNBC. Data were analyzed by using SPSS software (P < 0.001, Pearson’s test)CC BY · PubMed Central
Fig. 2 Aur-A promotes cell proliferation and invasion through activation of mTOR in TNBC cell lines. a, b Inhibition or silencing of Aur-A decreases both p-Aur-A and p-mTOR in TNBC cells. Cells were incubated with indicated doses of MLN8237 (0, 0.25, 0.5, 1, and 2 μM) for 48 h or transfected with siRNAs targeting Aur-A, followed by IB analysis. c Overexpression of Aur-A-WT increases p-mTOR, but its dead mutant decreases p-mTOR. Cells were transfected with indicated plasmids and collected for IB assay after transfection. d–f Silencing Aur-A inhibits cell proliferation and suppresses migration by decreasing p-mTOR. Cells were transfected with siRNAs targeting Aur-A and then collected for IB assay (d), ATPlite assay (e), or transwell migration assay (f) (mean ± SD; **P < 0.01). g–i Overexpression of Aur-A promotes cell proliferation and migration by activating mTOR and simultaneously silencing mTOR abrogates these effects. Cells were initially transfected with vector control or FLAG-tagged Aur-A first and then silenced using siRNAs targeting control or mTOR, followed by IB (g), ATPlite (h), and transwell migration (i) assays (mean ± SD; *P < 0.05; **P < 0.01)
Fig. 2 Aur-A promotes cell proliferation and invasion through activation of mTOR in TNBC cell lines. a, b Inhibition or silencing of Aur-A decreases both p-Aur-A and p-mTOR in TNBC cells. Cells were incubated with indicated doses of MLN8237 (0, 0.25, 0.5, 1, and 2 μM) for 48 h or transfected with siRNAs targeting Aur-A, followed by IB analysis. c Overexpression of Aur-A-WT increases p-mTOR, but its dead mutant decreases p-mTOR. Cells were transfected with indicated plasmids and collected for IB assay after transfection. d–f Silencing Aur-A inhibits cell proliferation and suppresses migration by decreasing p-mTOR. Cells were transfected with siRNAs targeting Aur-A and then collected for IB assay (d), ATPlite assay (e), or transwell migration assay (f) (mean ± SD; **P < 0.01). g–i Overexpression of Aur-A promotes cell proliferation and migration by activating mTOR and simultaneously silencing mTOR abrogates these effects. Cells were initially transfected with vector control or FLAG-tagged Aur-A first and then silenced using siRNAs targeting control or mTOR, followed by IB (g), ATPlite (h), and transwell migration (i) assays (mean ± SD; *P < 0.05; **P < 0.01)CC BY · PubMed Central
Fig. 3 Aur-A activates mTOR through ERK1/2 pathway. a Silencing Aur-A decreased p-mTOR and p-ERK1/2. Cells were transfected with siRNAs targeting control or Aur-A, followed by the IB assay 48 h post transfection. b, c Silencing ERK1/2 decreased p-mTOR, but silencing mTOR failed to change the level of p-ERK1/2. Cells were transfected with siRNAs targeting control or ERK1/2 (b) or mTOR (c), followed by the IB assay. d, e Silencing or inhibition of ERK1/2 significantly rescued the increase of p-mTOR caused by Aur-A overexpression. Cells were transfected with vector or FLAG-Aur-A, along with transfection of siRNAs targeting control or ERK1/2 (d), or treatment with DMSO or U0126 (e). f, g Silencing or inhibition of mTOR failed to rescue the increase of p-ERK1/2 caused by Aur-A overexpression. Cells were transfected with vector or FLAG-Aur-A, along with transfection of siRNAs targeting control or mTOR (f), or treatment with DMSO or rapamycin (g)
Fig. 3 Aur-A activates mTOR through ERK1/2 pathway. a Silencing Aur-A decreased p-mTOR and p-ERK1/2. Cells were transfected with siRNAs targeting control or Aur-A, followed by the IB assay 48 h post transfection. b, c Silencing ERK1/2 decreased p-mTOR, but silencing mTOR failed to change the level of p-ERK1/2. Cells were transfected with siRNAs targeting control or ERK1/2 (b) or mTOR (c), followed by the IB assay. d, e Silencing or inhibition of ERK1/2 significantly rescued the increase of p-mTOR caused by Aur-A overexpression. Cells were transfected with vector or FLAG-Aur-A, along with transfection of siRNAs targeting control or ERK1/2 (d), or treatment with DMSO or U0126 (e). f, g Silencing or inhibition of mTOR failed to rescue the increase of p-ERK1/2 caused by Aur-A overexpression. Cells were transfected with vector or FLAG-Aur-A, along with transfection of siRNAs targeting control or mTOR (f), or treatment with DMSO or rapamycin (g)CC BY · PubMed Central
Fig. 4 MLN8237 and rapamycin show synergistic effects in TNBC cell lines. a, b IC50 values of MLN8237 and rapamycin in five TNBC cell lines. Each cell line was treated with the indicated concentrations of MLN8237 (0.019, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5, and 10 μM) (a) or rapamycin (0.019, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5 and 10 μM) (b) for 48 h, followed by the ATPlite assay, IC50 of the two compounds were determined by GraphPad Prism5 software. c MLN8237 and rapamycin show synergistic effects in MDA-MB-231 cells. CI-effect plots and median effect plots were generated using CalcuSyn software. The points a, b, and c represent CI values for the combinations 0.1, 0.2, and 0.4 μM MLN8237 with 0.5, 1.0, and 2.0 μM rapamycin in a constant ratio, respectively. d Combination of MLN8237 and rapamycin inhibits cell colony formation in TNBC cells. MDA-MB-231 cells were treated with MLN8237 (0.2 μM) or rapamycin (1.0 μM) alone or combination of the two compounds, followed by the colonogenic assay. The data were expressed as mean ± S.D. (*P < 0.05, **P < 0.01; Student’s t-test) compared with control groups. e, f Dual inhibition of Aur-A and rapamycin suppressed cell proliferation and induced apoptosis in TNBC cells. Cells were treated with MLN8237 (0.2 μM) or rapamycin (1.0 μM), or combination of the two compounds, followed by the IB assay with indicated antibodies
Fig. 4 MLN8237 and rapamycin show synergistic effects in TNBC cell lines. a, b IC50 values of MLN8237 and rapamycin in five TNBC cell lines. Each cell line was treated with the indicated concentrations of MLN8237 (0.019, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5, and 10 μM) (a) or rapamycin (0.019, 0.039, 0.078, 0.156, 0.312, 0.625, 1.25, 2.5, 5 and 10 μM) (b) for 48 h, followed by the ATPlite assay, IC50 of the two compounds were determined by GraphPad Prism5 software. c MLN8237 and rapamycin show synergistic effects in MDA-MB-231 cells. CI-effect plots and median effect plots were generated using CalcuSyn software. The points a, b, and c represent CI values for the combinations 0.1, 0.2, and 0.4 μM MLN8237 with 0.5, 1.0, and 2.0 μM rapamycin in a constant ratio, respectively. d Combination of MLN8237 and rapamycin inhibits cell colony formation in TNBC cells. MDA-MB-231 cells were treated with MLN8237 (0.2 μM) or rapamycin (1.0 μM) alone or combination of the two compounds, followed by the colonogenic assay. The data were expressed as mean ± S.D. (*P < 0.05, **P < 0.01; Student’s t-test) compared with control groups. e, f Dual inhibition of Aur-A and rapamycin suppressed cell proliferation and induced apoptosis in TNBC cells. Cells were treated with MLN8237 (0.2 μM) or rapamycin (1.0 μM), or combination of the two compounds, followed by the IB assay with indicated antibodiesCC BY · PubMed Central
Fig. 5 MLN8237 and rapamycin synergistically inhibit TNBC tumor growth in xenograft model. a, b Synergistic antitumor activity of MLN8237 and rapamycin in the MDA-MB-231 xenograft model. MDA-MB-231 cells were injected subcutaneously into both flank sides of nude mice. The mice were randomized when the tumor size reached 100 mm3 and were treated as follows: vehicle, n = 5; MLN8237 (30 mg/kg/days for 5 days/week for 4 weeks), n = 5; rapamycin (3.75 mg/kg/days for 5 days/week for 4 weeks), n = 5; MLN8237 + rapamycin, n = 5. The tumor growth was monitored and growth curve was plotted (a) and tumors were harvested and photographed (b). Data represent the mean ± SEM (*p < 0.05, **p < 0.01; Student’s t-test). c Both of the compounds were well tolerated in mice. Body weight was measured during the treatment and plotted (mean ± SEM). d Immunohistochemical staining of xenograft tumor tissues. Tumor tissues from four groups of mice were fixed, sectioned, and stained with indicated antibodies. Scale bars: 100 μm. Shown are mean ± SEM, *P < 0.05; **P < 0.01
Fig. 5 MLN8237 and rapamycin synergistically inhibit TNBC tumor growth in xenograft model. a, b Synergistic antitumor activity of MLN8237 and rapamycin in the MDA-MB-231 xenograft model. MDA-MB-231 cells were injected subcutaneously into both flank sides of nude mice. The mice were randomized when the tumor size reached 100 mm3 and were treated as follows: vehicle, n = 5; MLN8237 (30 mg/kg/days for 5 days/week for 4 weeks), n = 5; rapamycin (3.75 mg/kg/days for 5 days/week for 4 weeks), n = 5; MLN8237 + rapamycin, n = 5. The tumor growth was monitored and growth curve was plotted (a) and tumors were harvested and photographed (b). Data represent the mean ± SEM (*p < 0.05, **p < 0.01; Student’s t-test). c Both of the compounds were well tolerated in mice. Body weight was measured during the treatment and plotted (mean ± SEM). d Immunohistochemical staining of xenograft tumor tissues. Tumor tissues from four groups of mice were fixed, sectioned, and stained with indicated antibodies. Scale bars: 100 μm. Shown are mean ± SEM, *P < 0.05; **P < 0.01CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 38

Metadata

Authors
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J.
Affiliations
  • Nanchang University (CN)
  • Tongji Hospital (CN)
  • Third Hospital of Nanchang (CN)
  • Army Medical University (CN)
  • University of Michigan (US)
Corresponding author
  • Li, Zhangyun
  • Xu, Jie
Venue
Cell Death & Disease
Published
2019-08-13
Volume
10
Issue
8
Pages
606-606
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2968684419
Cited by
38
References
54
Citations by year
2026: 4 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 5
FWCI
1.16
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
National Natural Science Foundation of China (81402194, 81670439)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
triple-negative breast cancer, AURKA, mTOR signaling, ERK1/2, synthetic lethality, dual-targeted therapy, cell proliferation, cell migration, therapeutic target
MeSH terms
Synthetic Lethal Mutations, Animals, Antineoplastic Agents, Azepines, Drug Synergism, Enzyme Activation, Female, Humans, Mice, Nude, Neoplasm Invasiveness, Pyrimidines, Disease Progression, Sirolimus, Inhibitory Concentration 50, Gene Silencing, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, TOR Serine-Threonine Kinases, Aurora Kinase A, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality. https://app.cochat.ai/papers/10.1038/s41419-019-1855-z
The paper
Zhang, W., Xia, D., Li, Z., Zhou, T., Chen, T., Wu, Z., Zhou, W., Li, Z., Li, L., & Xu, J. (2019). Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality. Cell Death & Disease. https://doi.org/10.1038/s41419-019-1855-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.